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Abstract
Background: Low serum amylase levels may reflect impaired exocrine-endocrine relationship in the pancreas.
However, few clinical studies have addressed this issue. Therefore, in this epidemiological study, we investigated
whether low serum amylase was associated with the pathogenesis of impaired insulin action: metabolic syndrome
(MetS) and diabetes.
Research Design and Methods: Serum amylase, cardiometabolic risk factors, MetS (Adult Treatment Panel III
criteria), and diabetes were examined in 2,425 asymptomatic subjects aged 30-80 years who underwent medical
checkups recently (April 2009-March 2010) and 5 years ago.
Results: Clinical variables, except for age and estimated glomerular filtration rate (eGFR), shifted favorably with
increasing serum amylase levels. Plasma glucose levels at 1- and 2-hr during OGTT increased significantly with
decreasing serum amylase levels. Multiple logistic analyses showed that, compared with highest quartile of serum
amylase, lowest quartile was associated with increased risk for MetS and diabetes after adjustment for confounding
factors [odds ratio (95% CI), 2.07 (1.39-3.07) and 2.76 (1.49-5.11), respectively]. In subjects who underwent checkups
5 years ago (n = 571), lower amylase at the previous checkup were associated with larger numbers of metabolic
abnormalities at the recent checkup. The fluctuation over time in serum amylase levels in subjects with low serum
amylase at the previous checkup was slight and was unaffected by kidney dysfunction.
Conclusions: Our results indicate that low serum amylase is associated with increased risk of metabolic
abnormalities, MetS and diabetes. These results suggest a pancreatic exocrine-endocrine relationship in certain
clinical conditions.
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Introduction
Elevated serum amylase levels often accompany acute
pancreatitis [1-3] and are occasionally caused by other
conditions such as pancreatic tumors, diabetic ketoaci-
dosis and kidney dysfunction [1-6]. In contrast, low
serum amylase is thought to be due to diffuse pancreas
destruction secondary to advanced chronic pancreatitis
or alcoholic disease [7-9]. Low serum amylase is also
associated with insulin deficiency in patients with type 1
diabetes and, less commonly, with type 2 diabetes
[10-13], as well as the pathogenesis of insulin resistance
in obese animal models [14,15]. Because serum amylase
can be classified as pancreatic-type and salivary-type
amylase [2,3], it is often necessary to distinguish
between the two types for precise clinical diagnosis.
Nevertheless, the measurement of serum amylase is use-
ful to determine the pathogenesis of many diseases.
To date, the clinical relevance of low serum amylase
levels remains poorly understood. Animal and cellular
studies regarding the relationship between the endocrine
and the exocrine pancreas have consistently showed that
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via the islet-acinar axis [16-19]. Briefly, insulin binds to
its receptor on acinar cells and stimulates amylase secre-
tion through various pathways [17-19]. However, the
nature of this relationship between low serum amylase
and clinical conditions has been addressed by relatively
few, small-scale human studies that yielded some con-
flicting results [10-13,19,20].
To date, no large-scale epidemiological studies have
been conducted to explore the relationship between low
serum amylase levels and cardiometabolic diseases asso-
ciated with insulin resistance and/or inadequate insulin
secretion, such as metabolic syndrome (MetS) and dia-
betes. Therefore, the aim of this epidemiological study
was to determine whether low serum amylase levels are
associated with cardiometabolic risk factors, MetS, and
diabetes, which could yield insight into a possible exo-
crine-endocrine relationship in clinical conditions. In
this context, we examined these associations in a cross-
sectional community study of asymptomatic adults. In
addition, because some proportion of the participants
underwent checkups 5 years ago, we retrospectively
evaluated whether the previous low serum amylase was
associated with MetS, diabetes, and changes in meta-
bolic abnormalities over time. Fluctuations in serum
amylase levels were also examined according to kidney
function assessed by estimated glomerular filtration rate
(eGFR), which often deteriorates following the develop-
ment of MetS and diabetes, and is a key factor that
increases serum amylase [2-6].
Methods
Subjects
The subjects in this study were asymptomatic adults
aged 30-80 years who lived in the suburbs of Saitama,
Japan, and underwent thorough medical checkups at
Social Insurance Omiya General Hospital, Saitama,
Japan. The present report represents a series of observa-
tional studies performed in collaboration with Josai Uni-
versity, Sakado, Japan and Social Insurance Omiya
General Hospital that have been conducted using data
collected between April 2009 and March 2010 to eluci-
date the relationships between lifestyle-related diseases
and cardiometabolic factors. The protocol was approved
by The Ethics Committee of Josai University and the
Council of the Hospital, and informed consent was
obtained from all participants. All subjects who under-
went a medical checkup were recruited in this study,
without any special selections. However, subjects with
C-reactive protein (CRP) ≥ 10.0 mg/l, eGFR ≤ 35 ml/
min/1.73 m
2, serum amylase ≤ 30 IU/l or ≥ 200 IU/l,
and those suspected of having cancer or endocrinopa-
thies were excluded from the study. Consequently, a
total of 2,425 individuals were included in this study,
which included 571 individuals who underwent check-
ups 5 years ago.
Anthropometric and laboratory measurements
Blood tests, anthropometric tests, blood pressure tests
and abdominal ultrasound scans (to screen for liver,
gallbladder, pancreas and adrenal gland diseases) were
carried out after an overnight fast. Serum parameters
were measured using an autoanalyzer (Hitachi. Tokyo,
Japan). The serum amylase level was measured using an
enzymatic method (L-type Amylase, Wako, Tokyo,
Japan) with a normal range of 41-112 IU/l, a detection
limit of 1.7 IU/l, and a run-to-run coefficient of varia-
tion < 5.0%. Plasma glucose was measured by the glu-
cose oxidase method. HbA1c was measured in Japan
Diabetes Society (JDS)-HbA1c units by high-perfor-
mance liquid chromatography. HbA1c was converted to
National Glycohemoglobin Standardization Program
(NGSP) levels by the formula HbA1c (%) (NGSP) =
HbA1c (JDS) (%) + 0.4%, considering the relational
expression of HbA1c (JDS) (%) measured by the pre-
vious Japanese standard substance and measurement
methods [21].
eGFR was calculated using the Modification Diet in
Renal Disease study equation for Japanese subjects [22],
as follows:
eGFR (ml/min/1.73m2) = 194 × serum Cr−1.094 × age−0.287 (if female) × 0.739
Cr: serum creatinine concentration (mg/dl).
The diagnosis of MetS was based on the Adult Treat-
ment Panel (ATP) III criteria [23] with the following
cutoff limits: 1) systolic blood pressure ≥ 130 mmHg or
diastolic blood pressure ≥ 85 mmHg; 2) triglyceride
(TG) ≥ 150 mg/dl; 3) low high-density lipoprotein cho-
lesterol (HDL-C) < 40 mg/dl for men and < 50 mg/dl
for women; 4) fasting plasma glucose (FPG) ≥ 100 mg/
dl; and 5) waist circumference ≥ 90 cm for men and ≥
80 cm for women. Subjects meeting three or more of
these criteria were defined as having MetS. If subjects
were treated for any of these components, they were
determined to meet that criterion. The number of ATP-
III-MetS components (NAMC) was recorded as an indi-
cator reflecting the severity of metabolic abnormalities.
Diabetes was defined as FPG ≥ 126 mg/dl or HbA1c ≥
6.5% according to the American Diabetes Association
diagnostic criteria [24], or being treated with oral hypo-
glycemic drugs or insulin. Most of the patients with dia-
betes in this study were considered to be type 2 diabetes
because this is much more prevalent (90-95%) [24],
although the exact diagnosis was not confirmed. Sub-
jects with prediabetes, those suspected of having dia-
betes, and those who wished to know their glucose
metabolic status in more detail, underwent a 75-g oral
glucose tolerance test (OGTT). Consequently, 1,244
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Of these subjects, 23 subjects were diagnosed as diabetes
afterward with a mean HbA1c of 6.4%.
Retrospective longitudinal subanalysis
A total of 707 subjects actually underwent a checkup at
the same hospital 5 years ago, and most of the para-
meters recorded at the current checkup, except for
waist circumference, were recorded previously. However,
136 subjects had already had MetS and/or diabetes,
which was retrospectively diagnosed with the identical
criteria described above, thereby those subject were
excluded from the cohort data. Consequently, 571 sub-
jects remained for the retrospective longitudinal subana-
lysis. Because waist circumference was not recorded at
the previous checkup, body mass index (BMI) ≥ 25 kg/
m
2 at that time was included in the MetS criteria
instead of elevated waist circumference. Accordingly,
such NAMC is termed as NAMC-BMI. Changes during
the periods in NAMC-BMI and proportions of its com-
ponents [elevated blood pressure, dyslipidemia (high TG
and/or low HDL), and elevated FPG] were examined
according to the quartiles of serum amylase. In addition,
changes in serum amylase during the periods were also
assessed according to the quartiles of serum amylase at
the previous checkup and three categories divided by
current kidney function.
Statistical analysis
The data are expressed as means ± SD or median/geo-
metric mean (interquartile range). Multiple stepwise
regression analysis was conducted to determine para-
meters that significantly explain the serum amylase
level. Dichotomous parameters were labeled as 0 and
1, respectively, before including as independent vari-
ables. Subjects were divided into quartiles of serum
amylase for current and previous levels. Clinical vari-
ables were compared with one-way analysis of variance
(ANOVA). Serum amylase was examined with two-way
ANOVA with four categories consisting of NAMC (0,
1, 2, and 3-5) as one factor and smoking status as
another factor. OGTT blood glucose levels were simi-
larly examined by two-way repeated ANOVA. In the
571 subjects included in the longitudinal analysis,
changes in NAMC-BMI over time were examined by
one way and two-way ANOVA. Multivariate logistic
regression models were used to examine the associa-
tions between lowest amylase quartile with MetS and
diabetes after adjustment for confounding factors (cur-
rent and historical parameters). Statistical analysis was
performed using SPSS software version 18.0 (SPSS-
IBM Chicago, IL). Values of p < 0.05 were considered
statistically significant.
Results
The clinical characteristics of subjects according to
serum amylase quartile are shown in Table 1. Across
increasing amylase quartiles, the prevalence of men,
smokers, daily alcohol consumption, infrequent exercise,
MetS, and diabetes decreased significantly. Most clinical
variables were decreased (HDL-C was increased) across
increasing amylase quartiles, except for age and eGFR
which showed unfavorable changes. Intriguingly, the
prevalence of history of stroke and medications for
hypercholesterolemia were higher in the highest quartile.
Unexpectedly, the statistical significance for the relation-
ship between HbA1c and serum amylase was weaker
(P = 0.02) than that of other variables. Of clinical para-
meters listed in Table 1, stepwise regression analysis
revealed that serum amylase level was significantly
explained by BMI, eGFR, smoking, age, daily alcohol
consumption, FPG, diastolic blood pressure, and trigly-
ceride (ß coefficient = -0.17, -0.17, -0.11, 0.11, -0.07,
-0.05, -0.05, and -0.04, respectively, data not shown).
Figure 1 shows serum amylase levels according to
NAMC categories. In both non-smokers and in smokers,
serum amylase levels decreased significantly with
increasing NAMC almost in parallel, with an approxi-
mately 10 IU/l decline in smokers. Figure 2 shows the
changes in plasma glucose levels during OGTTs accord-
ing to serum amylase quartiles. Because subjects with
definite diabetes did not undergo OGTT, overall
responses to OGTT showed a near-normal pattern.
Nevertheless, the plasma glucose levels at 1- and 2-hrs
increased significantly with decreasing amylase quartiles.
Multiple logistic analyses (Table 2) showed that, com-
pared with the highest amylase quartile, lowest quartile
was significantly associated with increased risk for MetS
and diabetes even after adjustment for clinical confoun-
ders including eGFR.
Retrospective analysis
We next repeated the analysis in subjects who underwent
the checkup 5 years ago (n = 571). In this analysis, BMI ≥
25 kg/m
2 was used for the determination of current and
previous MetS instead of elevated waist circumference.
As shown in Table 2, compared with the highest amylase
quartile at the previous checkup, the previous lowest
amylase quartile was significantly associated with current
MetS, but not current diabetes, which remained after
adjustment for confounding factors recorded at the pre-
vious checkup. Figure 3 shows the changes over time for
NAMC-BMI and its components according to previous
amylase quartiles. Subjects with lower amylase levels 5
years ago showed significantly greater increases in
NAMC-BMI (P = 0.02, Figure 3A) and proportions of
elevated blood pressure (P = 0.006, Figure 3B). Figure 4
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ing to previous amylase quartiles and three groups classi-
fied according to current eGFR. Overall a significant
inverse association between changes in serum amylase
and increasing previous amylase levels was observed (P <
0.0001). Although the serum amylase level in lowest
quartile 5 years ago increased slightly at the recent
checkup by ~5 IU/l, it was not affected by kidney dys-
function (eGFR < 60 ml/min/1.73 m
2), compared with
those in other quartiles.
Discussion
Although the pathogenic features of reduced amylase
secretion and the underlying mechanisms linking islets
and acinar cells have been extensively examined in ani-
mal and cellular studies [14-19], clinical evidence sup-
porting such exocrine-endocrine relationships has not
been established in large human studies. Our results in
this epidemiological study indicate that serum amylase
levels are inversely associated with most cardiometabolic
risk factors, especially those associated to obesity.
Furthermore, the serum amylase level decreased with
worsening of metabolic abnormalities and these declines
were independent of smoking, a strong factor for increas-
ing insulin resistance [25,26]. Meanwhile, the pattern of
changes in plasma glucose levels during the OGTTs sug-
gest that subjects with low serum amylase have lower
glucose tolerance. Significant associations of current and
previous low serum amylase with current MetS and dia-
betes (current low serum amylase only) were observed
and remained after adjustment for confounding factors.
Additionally, the severity of metabolic abnormalities wor-
sened over 5 years in subjects with low serum amylase at
the previous checkup. Accordingly, our results suggest
that low serum amylase levels may reflect metabolic
abnormalities and abnormal glucose metabolism, both of
which are associated with impaired insulin action due to
insulin resistance and/or inadequate insulin secretion.
Table 1 Characteristics of subjects according to serum amylase quartiles
Total Q1 (Lowest) Q2 Q3 Q4 (Highest) P value
n 2,425 610 585 613 617
Men, n (%) 1,589 (65.5) 428 (70.2) 419 (71.6) 376 (61.3) 366 (59.3) < 0.0001*
Age, y 53.8 ± 11.9 51.1 ± 11.0 51.9 ± 11.4 54.6 ± 12.1 57.4 ± 12.0 < 0.0001
BMI, kg/m
2 23.3 ± 3.2 24.3 ± 3.4 23.5 ± 3.1 23.1 ± 3.1 22.3 ± 2.9 < 0.0001
Waist circumference, cm 82.1 ± 8.8 84.6 ± 9.0 82.9 ± 8.5 81.7 ± 8.7 79.2 ± 8.3 < 0.0001
Systolic blood pressure, mmHg 122 ± 19.0 125 ± 19.2 121 ± 18.2 121 ± 19.4 120 ± 18.8 0.0002
Diastolic blood pressure, mmHg 75.7 ± 12.8 78.1 ±13.1 76.0 ± 12.8 74.9 ± 12.4 73.9 ±12.4 < 0.0001
g-glutamyltransferase, IU/l 26 (18-45) 32 (22-55) 28 (18-48) 24 (17-40) 23 (16-38) < 0.0001
Amylase, IU/l (range) 74.0 ± 23.6
(31-193)
48.7 ± 6.3
(31-57)
63.4 ± 3.5
(58-69)
77.5 ± 4.8
(70-86)
106 ± 19.1
(87-193)
–
Total cholesterol, mg/dl 205 ± 33.9 205 ± 33.7 204 ± 33.9 205 ± 32.8 208 ± 35.3 0.18
Triglyceride, mg/dl 94 (68-136) 110 (75-159) 95 (69-140) 92 (66-132) 85 (63-123) < 0.0001
HDL-C, mg/dl 61.0 ± 14.9 58.3 ± 14.2 59.9 ± 14.1 61.7 ± 15.4 63.9 ± 15.3 < 0.0001
Fasting plasma glucose, mg/dl 101 ± 18.1 104 ± 23.0 101 ± 18.3 99.8 ± 14.8 98.8 ± 14.6 < 0.0001
HbA1c, % 5.75 ± 0.61 5.81 ± 0.79 5.75 ± 0.65 5.71 ± 0.45 5.74 ± 0.51 0.02
CRP, mg/l 0.53 (0.30-0.70) 0.62 (0.30-1.15) 0.51 (0.30-0.70) 0.52 (0.30-0.80) 0.47 (0.30-0.70) < 0.0001
eGFR, ml/min/1.73 m
2 76.0 ± 13.9 79.7 ± 13.2 77.7 ± 13.5 75.0 ± 13.3 72.0 ± 14.4 < 0.0001
Metabolic syndrome, n (%) 438 (18.1) 155 (25.4) 111 (19.0) 105 (17.1) 67 (10.9) < 0.0001*
Diabetes, n (%) 201 (8.3) 75 (12.3) 47 (8.0) 38 (6.2) 41 (6.6) 0.0004*
Medical history of
Cardiovascular diseases, n (%) 85 (3.5) 19 (3.1) 13 (2.2) 26 (4.2) 27 (4.4) 0.14*
Stroke, n (%) 41 (1.7) 6 (1.0) 5 (0.9) 10 (1.6) 20 (3.2) 0.004*
Medications for
Hypertension, n (%) 413 (17.0) 103 (16.9) 98 (16.8) 96 (15.7) 116 (18.8) 0.52*
Hypercholesterolemia, n (%) 254 (10.5) 61 (10.0) 55 (9.4) 51 (8.3) 87 (14.1) 0.006*
Diabetes, n (%) 81 (3.3) 23 (3.8) 16 (2.7) 18 (2.9) 24 (3.9) 0.59*
Current smoker, n (%) 629 (25.9) 236 (38.7) 177 (30.3) 125 (20.4) 91 (14.7) < 0.0001*
Daily alcohol consumption, n (%) 757 (31.2) 224 (36.7) 203 (34.7) 170 (27.7) 160 (25.9) < 0.0001*
Infrequent exercise, n (%) 1,650 (68.0) 448 (73.4) 405 (69.2) 416 (67.9) 381 (61.8) 0.0002*
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate. Data are means ± SD. g-
glutamyltransferase, triglyceride and CRP are expressed as medians/geometric means (interquartile range). g-glutamyltransferase, triglyceride and CRP levels were
examined after Log10-transformation because they were highly skewed. P-values were determined by ANOVA, except * by c
2-test.
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dysfunction contributes to elevations in serum amylase
levels because the kidney plays the main role in elimi-
nating circulating amylase [2-6]. Nevertheless, the fluc-
tuation in serum amylase levels in subjects in the lowest
quartile 5 years ago was not affected by kidney dysfunc-
tion (Figure 4), suggesting that low serum amylase may
be a stable marker for cardiometabolic disorders related
to impaired insulin action. One reason for the decrease
over 5 years in the highest quartile 5 years ago is that
Figure 1 Serum amylase levels according to the number of
ATP-III-MetS components (NAMC). The numbers of nonsmokers
with NAMCs of 0, 1, 2 and 3-5 are 472, 580, 438 and 306,
respectively. The numbers of smokers with NAMCs of 0, 1, 2 and 3-5
are 169, 184, 144 and 132, respectively. The serum amylase level
decreased significantly with increasing NAMC in both nonsmokers
and smokers (both P < 0.0001, ANOVA), and was significantly
different between nonsmokers and smokers (P < 0.0001, ANOVA).
White triangles = nonsmokers, black triangles = smokers. Values are
means ± SE.
Figure 2 Plasma glucose levels during OGTTs.T h en u m b e r so f
subjects in Q1, Q2, Q3 and Q4 are 290, 312, 322 and 320,
respectively. The cutoff values for each quartile are presented in
Table 1. Plasma glucose levels increased significantly with
decreasing serum amylase levels (P = 0.002, ANOVA). Values are
means ± SE.
Table 2 Associations between serum amylase quartiles
with MetS and diabetes
Model 1 Model 2 Model 3
Current amylase quartiles* MetS
Q1 (Lowest) 2.79 (2.04-
3.82)
3.30 (2.38-
4.57)
2.07 (1.39-
3.07)
Q2 1.92 (1.38-
2.66)
2.21 (1.58-
3.09)
1.70 (1.14-
2.54)
Q3 1.69 (1.22-
2.35)
1.85 (1.32-
2.58)
1.56 (1.05-
2.31)
Q4 (Highest) reference 1 1 1
P for trend 0.02 0.02 0.03
Diabetes
Q1 (Lowest) 1.97 (1.32-
2.93)
2.73 (1.79-
4.18)
2.76 (1.49-
5.11)
Q2 1.23 (0.79-
1.89)
1.57 (1.00-
2.46)
1.95 (1.03-
3.68)
Q3 0.93 (0.59-
1.47)
1.07 (0.67-
1.70)
1.16 (0.59-
2.29)
Q4 (Highest) reference 1 1 1
P for trend 0.13 0.08 0.03
Prior amylase quartiles (n =
571) **
MetS
Q1 (Lowest) 4.21 (1.81-
9.76)
4.82 (2.01-
11.5)
5.88 (2.05-
16.8)
Q2 3.37 (1.47-
7.72)
3.78 (1.61-
8.85)
3.97 (1.45-
10.8)
Q3 1.22 (0.47-
3.19)
1.34 (0.51-
3.53)
1.68 (0.54-
5.19)
Q4 (Highest) reference 1 1 1
P for trend 0.04 0.04 0.02
Diabetes
Q1 (Lowest) 3.70 (0.73-
18.7)
3.74 (0.68-
20.6)
3.26 (0.45-
23.4)
Q2 0.92 (0.13-
6.59)
0.91 (0.12-
6.89)
0.60 (0.06-
5.56)
Q3 1.46 (0.24-
8.86)
1.65 (0.26-
10.5)
1.78 (0.23-
14.1)
Q4 (Highest) reference 1 1 1
P for trend 0.25 0.27 0.38
Model 1: unadjusted; Model 2: adjusted for age, sex, and current smoking
(versus non-smokers); Model 3: Model 2 plus adjustment for infrequent
exercise (versus frequent exercise), daily alcohol consumption (versus
infrequent/no alcohol consumption), BMI, CRP and eGFR. *Current quartiles
are identical to those in Table 1. The numbers of subjects in the previous
amylase quartiles are 144, 149, 157, and 121 for Q1-Q4, respectively. **The
ranges of values for the prior serum amylase quartiles are 30-55, 56-69, 70-85
and 86-198 IU/l for Q1-Q4, respectively.
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improved before the current checkup. The most plausi-
ble explanation for the significant increase in propor-
tions of elevated blood pressure is that resultant
hyperinsulinemia may affect Na+ reabsorption by the
kidney and circulating volume retention, leading to
increased blood pressures. In contrast, dyslipidemia and
abnormal FPG in subjects in the lowest quartile were
already evident and did not deteriorate thereafter, as
compared with those in other quartiles. Furthermore,
t h es m a l ls a m p l es i z ei nc o h o r td a t am a yi n t e r f e r ew i t h
the outcomes. Noteworthy, the finding that prevalence
of history of stroke was increased in subjects with
higher amylase (Table 1) may be contradicting. How-
ever, this might be consistent with the recent report
that reduced eGFR, which was observed with increasing
serum amylase in this study, was associated with
increased intima-media thickness of the carotid artery
in patients with type 2 diabetes [27]. Furthermore, it is
unclear why the prevalence of treatment for hypercho-
lesterolemia mostly with statins was higher in subjects
with higher amylase levels (Table 1). Therefore, large
cross-sectional and prospective studies will be needed
for the exploration of relationship between low serum
amylase and metabolic abnormalities as well as the
treatment with medications.
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Figure 3 Changes over 5 years for NAMC-BMI and its components. A: NAMC-BMI, B: Proportion of elevated blood pressure, C: Proportion of
high FPG, D: Proportion of dyslipidemia. The numbers of subjects in Q1, Q2, Q3 and Q4 are 144, 149, 157, and 121, respectively. NAMC-BMI and
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amylase levels were believed to be due to deficient insulin
activity [10-13], which is consistent with early findings
that insulin and ciglitazone (this drug was never
approved for clinical use), a peroxisome proliferator-acti-
vated receptor-g agonist respectively increased and
restored the secretion of amylase from pancreases iso-
lated from rats [15,16]. In contrast, the results of our ret-
rospective longitudinal analysis suggest that low serum
amylase levels preceded the overt metabolic abnormal-
ities. Alternatively, as proposed by Dandona et al. [11], a
common pathological process exists in the pancreas that
simultaneously affects the endocrine and exocrine com-
ponents of the pancreas. Consistent with this notion,
Hayden et al. [28] suggested that a continuous interstitial
matrix connection between endocrine and exocrine is
lost in animal models and humans with type 2 diabetes,
resulting in a dysfunctional insulino-acinar-ductal-incre-
tin gut hormone axis. Besides these putative mechanisms,
there are multiple defects in insulin secretion and signal-
ing in type 2 diabetes [24,28], which might be associated
with the low amylase secretion from the pancreas.
Several limitations of this study should be mentioned.
First, the blood insulin levels were not measured. How-
ever, previous studies have shown positive correlations
between amylase secretion and circulating C-peptide or
24-hr urinary C-peptide excretion in diabetic patients,
principally in type 1 diabetes [10-12], suggesting that
low circulating amylase may reflect low insulin secre-
tion. Nevertheless, obese people with MetS and type 2
diabetes tend to show hyperinsulinemia to compensate
for insulin resistance. Therefore, whether low serum
amylase levels are truly associated with hypoinsulinemia
or hyperinsulinemia is unclear. Measurement of insulin
levels would help confirm the associations observed in
this study, including the weak association between
HbA1c and serum amylase. Second, although it has
been reported that pancreatic serum amylase secretion
was decreased in the presence of hyperglycemia [2], the
actual level of pancreatic amylase relative to salivary
amylase in subjects with low ‘total serum amylase’ is
unknown and should be determined.
In conclusion, our study demonstrated that serum
amylase levels may be inversely related with many cardi-
ometabolic risk factors. Furthermore, low serum amylase
levels may be unchangeable even in the presence of kid-
ney dysfunction and are independently associated with
MetS and diabetes, suggesting a possible exocrine-endo-
crine relationship in various clinical conditions. The
causality, underlying mechanisms, and whether low
serum amylase is a valuable marker for these states
remain to be elucidated.
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Figure 4 Changes in serum amylase over 5 years. The numbers of subjects in Q1, Q2, Q3 and Q4 [further divided according to current
kidney functions as eGFR (ml/min/1.73 m
2)] are 144 (25, 105, 14), 149 (16, 120, 13), 157 (17, 116, 24), and 121 (9, 86, 26), respectively. Current
serum amylase increased significantly with decreasing amylase quartile recorded 5 years ago and decreasing current eGFR (P = 0.004 and P =
0.02, ANOVA, respectively). Values are means ± SE.
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